Book
← All deal pages
Deal page · Announced June 25, 2026

Merck KGaA, Darmstadt, Germany agreed to buy Bio-Techne. What the months before close decide for the people who built it.

An all cash deal, $73 a share, about $11.3 billion in enterprise value. In its quarterly report dated November 6, 2026, Bio-Techne said the merger was expected to close by late 2026 or early 2027. If you hold Bio-Techne RSUs, PSUs, options or ESPP shares, the decisions are already in front of you. This page is the public record, the timeline, and the questions to ask before close.

Facts checked November 16, 2026.

Mateo DellovoFounded BFA Wealth Management in 2015

Fiduciary adviser. Advisory fees only. Check my record

The deal, from the public record
  • Announced June 25, 2026 by Merck KGaA and Bio-Techne. The merger agreement is dated June 25, 2026. The joint press release says the deal was approved by Bio-Techne’s board of directors and by the relevant corporate bodies of Merck KGaA.
  • This page is about Merck KGaA, a German company, not Merck & Co. Bio-Techne’s employee Q&A of June 25, 2026 says Merck KGaA is a different company than Merck & Co.
  • Consideration is all cash, $73 for each share of Bio-Techne common stock, without interest and less any required tax withholding (Section 2.01(a)(i) of the merger agreement). The joint press release says the price represents an enterprise value of approximately $11.3 billion.
  • Expected close, as the companies stated at announcement, by late 2026 or early 2027, subject to customary closing conditions, including required regulatory approvals and approval by Bio-Techne’s shareholders. Bio-Techne repeated that timing in its quarterly report dated November 6, 2026, and its employee FAQ of September 9, 2026 said a specific closing date had not been scheduled. In its third quarter results release of November 12, 2026, Merck KGaA said its guidance reflected the acquisition of Bio-Techne for the month of December 2026, called this an assumption, and said the actual closing date may differ.
  • The closing conditions include approval by Bio-Techne’s shareholders, the end of the waiting period under the Hart-Scott-Rodino Act, and approvals under antitrust and investment screening laws in the jurisdictions listed in a disclosure letter that isn’t in the filed agreement (Section 6.01(a) and (b)).
  • Bio-Techne said its shareholders approved the merger agreement at a special meeting on September 23, 2026, and that the Hart-Scott-Rodino waiting period expired on September 18, 2026. It told employees on August 25, 2026 that the deal received unconditional approval from the German Federal Cartel Office on August 17, 2026, and on September 9, 2026 that approvals in other countries were in process. Its September 23, 2026 release said closing was subject to customary conditions, including receipt of remaining required regulatory approvals.
  • Either Merck KGaA or Bio-Techne can generally end the agreement if the merger has not closed by March 25, 2027. If the conditions still open on that date all relate to antitrust or investment screening law, and every other condition has been met, waived or can be met, the date extends automatically to June 25, 2027. If that is still true on June 25, 2027, it extends again to September 25, 2027, a Saturday. The parties can agree in writing to extend it further (Section 7.01(b)(i)).
  • Closing takes place on the fifth business day after the last closing condition is met or waived, unless the parties agree in writing on another date (Section 1.02). When the merger takes effect, Bio-Techne survives as a wholly owned subsidiary of Merck KGaA, and Bio-Techne’s proxy statement says its shares will no longer be listed or traded on Nasdaq.
  • Vested options with an exercise price below $73 are cancelled at close for cash equal to $73 minus the exercise price for each share, less tax withholding, due no later than the first administratively practicable payroll period after close (Section 2.03(a)(i) and (g)). Options with an exercise price of $73 or more are cancelled with no payment, whether or not vested (Section 2.03(a)).
  • Unvested options with an exercise price below $73 become fixed cash awards for the same amount, $73 minus the exercise price for each share. Each piece vests on the option’s schedule, including any acceleration terms, and is paid within 15 business days after it vests. Performance conditions on an option count at target (Section 2.03(a)(ii)).
  • RSUs that vest with time alone, whether vested or unvested at close, become fixed cash awards of $73 for each RSU, rounded to the nearest cent, under generally the same terms, including service based and accelerated vesting terms (Section 2.03(b)). Bio-Techne told employees on July 9, 2026 that these cash awards would continue to vest and be paid, less tax withholding, on the same time based schedule. Restricted stock becomes a similar fixed cash award, with any performance conditions counted at target (Section 2.03(d)).
  • PSUs become the same kind of fixed cash award, $73 for each unit, on generally the same terms, including service based and accelerated vesting terms. For any performance period not completed at close, the number of units counts at maximum performance, and the award then vests on service alone (Section 2.03(c)). Any award payment under Section 2.03 that is deferred compensation under Section 409A is instead paid at the earliest time its terms allow without a Section 409A tax or penalty (Section 2.03(g)).
  • Bio-Techne told employees on July 9, 2026 that the ESPP cycle then running would end as scheduled in August 2026, with contributions used to buy shares at its end, and on September 9, 2026 that the cycle had ended as scheduled and no new cycle would begin. Under the merger agreement, no new phase of the plan starts and the plan ends no later than just before close (Section 2.03(f)). ESPP shares you still hold at close become $73 in cash, like any other Bio-Techne share (Section 2.01(a)(i)). Bio-Techne’s annual report says its 2014 Employee Stock Purchase Plan is designed to comply with IRS provisions governing employee stock purchase plans.
  • In the merger agreement, Merck KGaA agreed with Bio-Techne that for 12 months after the closing date, or less if your employment ends sooner, it would provide each Bio-Techne employee base pay no lower than before close. Total target cash compensation, which the agreement says is made up of base pay, target short term cash incentive opportunity and target equity or long term incentive opportunity, is to be no less favorable in the aggregate, and so are employee benefits, with some exclusions. Severance is to be no less favorable than what is set out in a disclosure letter that isn’t in the filed agreement (Section 5.10(a)). The agreement says Merck KGaA does not have to keep anyone employed for any specific period, and that no employee is a third party beneficiary of the agreement, which generally means employees can’t enforce these terms themselves (Section 5.10(a) and (j)).
  • On the first regularly scheduled payroll date after the closing date, each person employed by Bio-Techne or its subsidiaries just before close is to be paid a pro rata annual bonus for the fiscal year of close. It is the greater of target and the bonus earned on actual performance through close, prorated for the part of that fiscal year before close. Any unpaid bonus for a fiscal year already completed is paid then too, at no less than actual performance (Section 5.10(d)). Bio-Techne’s fiscal year 2027 runs July 1, 2026 through June 30, 2027, and its September 9, 2026 employee FAQ said that if the deal closed before that year ended, bonuses would be prorated through close and paid following close.
  • Bio-Techne’s proxy statement says its compensation committee approved cash retention bonus agreements with its executive officers, senior vice presidents and vice presidents, and a retention bonus pool of up to $22,000,000. The pool is for critical talent or select employees below vice president level with a heavier workload related to the closing, and for payments to disqualified individuals under Section 280G, other than the named executive officers.
  • Bio-Techne told employees on September 9, 2026 that no decisions had been made regarding future workforce impacts, and that after close their years of service with Bio-Techne would generally be recognized under applicable Merck KGaA benefit plans, which may include eligibility, vesting, paid time off and severance. The FAQ says it is not legally binding, and that the merger agreement and plan documents control if they conflict.

Sources. Merck KGaA and Bio-Techne joint press release, June 25, 2026, Bio-Techne’s Form 8-K with the merger agreement dated June 25, 2026 as Exhibit 2.1, Bio-Techne’s definitive proxy statement, dated August 20, 2026, Bio-Techne’s employee communications of June 25, 2026, July 9, 2026, August 25, 2026 and September 9, 2026, filed with the SEC, Bio-Techne’s release of September 23, 2026 on the shareholder vote, Bio-Techne’s Form 10-Q for the quarter ended September 30, 2026, Bio-Techne’s Form 10-K for the fiscal year ended June 30, 2026, and Merck KGaA’s third quarter 2026 results release, November 12, 2026. BFA Wealth Management isn’t affiliated with Merck KGaA, Merck & Co. or Bio-Techne. The terms and dates above come from the announcement and filings named here, as of the date the facts were checked. They can change before close, so confirm the treatment of your own awards with HR before you act.

What an all cash deal means for Bio-Techne employees

In an all cash deal, the price is paid in cash, not stock. At close, each Bio-Techne share you own becomes $73 in cash. Bio-Techne’s proxy statement describes the cash exchange as generally a taxable transaction for U.S. federal income tax purposes, and the gain on shares held more than a year is generally long term. Shares from a Section 423 ESPP have two holding periods, more than two years from the grant date and more than one year from purchase. Part of the gain can be ordinary income even when both have passed. Cash for vested options with an exercise price below $73 is paid through payroll after close, less withholding. Federal withholding on supplemental pay can be a flat 22%, with 37% required above $1 million in a year, and that may be less than you owe. The guide for this part is Before Your Company Is Sold for Cash.

Unvested RSUs and PSUs, and unvested options with an exercise price below $73, generally don’t pay at close. They become fixed cash awards paid on your original vesting schedule as long as you meet its service terms, with PSUs counted at maximum performance for any period still open at close. So a stock grant becomes a fixed dollar amount landing on a schedule, and it no longer moves with any share price. RSUs and PSUs that have vested but not yet paid out become fixed cash awards too, on generally the same terms, so ask HR when those pay. Cash for RSUs and PSUs is taxed as pay. Whether a cash award speeds up if you are let go after close depends on the acceleration terms that applied to your award before close, which generally carry over.

Timing matters for the ESPP and your bonus. Bio-Techne said its last ESPP cycle ended as scheduled in August 2026 and that no new cycle would begin. Shares bought at the end of that cycle meet the more than one year from purchase test no earlier than August 2027, and your ESPP records show the exact purchase date. If close comes before a lot meets both holding periods, the cash out is generally a disqualifying disposition, with part of the value taxed as ordinary income. If close comes before fiscal 2027 ends on June 30, 2027, the merger agreement calls for a prorated fiscal 2027 bonus for people employed just before close, paid after close at no less than the prorated target.

The day after close, you hold no Bio-Techne stock and no Merck KGaA stock from this deal. What you have is cash, a tax bill to plan for if you have a gain, and any fixed cash awards still vesting on their schedule. That is the part worth planning before close.

The twelve questions to ask before close
  1. Which of my grants are paid in cash at close and which become fixed cash awards paid on my old vesting dates, and will HR confirm that for each grant in writing?
  2. For my PSUs, which performance periods will still be open at close, what does maximum performance mean for each grant, and how many units will each award count?
  3. Which of my options are priced at $73 or more and so pay nothing, and what will the others pay, and when?
  4. If I am let go without cause or leave for good reason after close, do my acceleration terms speed up my cash awards?
  5. If my role ends in the 12 months after close, what severance applies, and what would I have to sign to get it?
  6. Do I have a retention agreement or a retention pool award, and what does it require of me?
  7. What would my pro rata bonus for the year of close be at target and on actual results, and when is it paid?
  8. Could the golden parachute rules (Section 280G) reach me as an officer, a more than 1% owner or one of the highest paid 1% of employees, and would my deal payments reach three times my base amount, where a 20% excise tax can apply?
  9. If I hold ESPP shares or shares from an ISO exercise, will each lot be more than two years from its grant or offering date and more than one year from purchase or exercise when close cashes it out?
  10. What will withholding look like on the cash at close and on each cash award as it pays, and is a flat 22% federal rate, or 37% on supplemental pay above $1 million in a year, enough for my actual bracket?
  11. Should I sell Bio-Techne shares I own before close, when Bio-Techne’s insider trading policy allows, or hold them until close, and how does each choice change the tax year and whether my gain is long term?
  12. What happens to my awards if the deal does not close, and what would I do then?

Nobody at your company is paid to answer these for you. HR will tell you the mechanics. Your CPA will handle the return. The person who puts it all on one page, in the order it matters, is usually missing. That is the gap we fill.

The timeline

The months before close

Ask HR for the treatment of every award you hold, in writing, with the maximum PSU level for each grant and the definitions of cause and good reason that apply to you. Ask whether you have a retention agreement or award, and what it requires. Gather your grant agreements, ESPP and ISO records, and any severance terms. Decide on any share sale with a tax projection, not a guess.

The last 30 days before close

Closing takes place on the fifth business day after the last condition is met or waived, so the date can come with little notice. If you plan a sale before close, confirm when Bio-Techne’s insider trading policy lets you trade. Know what cash you will need for taxes, and when.

Close

Each Bio-Techne share you own becomes $73 in cash. Cash for vested options priced below $73 is due no later than the first administratively practicable payroll period after close, less withholding. If you are employed just before close, your pro rata bonus is due on the first regularly scheduled payroll date after close. Unvested RSUs, PSUs and options priced below $73 generally become fixed cash awards on your old vesting schedule. Keep every statement and confirmation for your tax return.

30 to 90 days after close

A plan for the cash, with the tax bill set aside first. A tax projection for the year of close and for each year a cash award pays, since cash for RSUs and PSUs is taxed as pay. A look at what the merger agreement says for pay, benefits and severance in the first 12 months, and what your own documents say after that. The job decision, if there is one.

The checklist. The twelve questions on one page, to bring to HR, your CPA, or your kitchen table. Leave your email and it is yours, along with the letters, two most weeks, unsubscribe any time.

Privacy Policy

Where BFA fits

We do this for tech and biotech people paid in stock. It starts with a free fifteen minute Checkup, then the Full Picture, a free hour on your whole situation, then the Plan. No commissions on investment products, advisory fees only.

Fifteen minutes, a straight answer either way. Nothing to prepare. If you know roughly what you hold and what HR has told you so far, that’s plenty.

Book a 15-minute Checkup

Not ready to book? Answer four quick questions, and you’ll see the first thing to check for your situation right away. I’ll also email you what to check next.

This page is general education from public filings, not advice for your situation. Neither BFA Wealth Management, LLC nor Mateo Dellovo has a business relationship with Merck KGaA, Merck & Co. or Bio-Techne or any nonpublic information about them. Terms can change before close.

This page covers events through the close of the deal. It is not updated after that.